BIOLASE, Inc.
BIOLQ
$0.0075
-$0.0014-15.73%
| Weiss Ratings | BIOLQ - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Very Weak | |||
| Risk Grade | E+ | |||
| Reward Grade | E | |||
| Rating Factors | BIOLQ - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Good | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Weak | |||
| Total Return Index | Very Weak | |||
| Volatility Index | Very Weak | |||
| Beta / Standard Deviation | BIOLQ - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 0.20 | |||
| Price History | BIOLQ - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -12.79% | |||
| 30-Day Total Return | -21.05% | |||
| 60-Day Total Return | -16.67% | |||
| 90-Day Total Return | -31.82% | |||
| Year to Date Total Return | -6.25% | |||
| 1-Year Total Return | -94.68% | |||
| 2-Year Total Return | -99.98% | |||
| 3-Year Total Return | -100.00% | |||
| 5-Year Total Return | -100.00% | |||
| 52-Week High % Change | -96.54% | |||
| 52-Week Low % Change | 122.50% | |||
| Price | BIOLQ - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $0.26 | |||
| 52-Week Low Price | $0.00 | |||
| 52-Week Low Price (Date) | Nov 08, 2024 | |||
| 52-Week High Price (Date) | Mar 22, 2024 | |||
| Valuation | BIOLQ - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 325.72K | |||
| Enterprise Value | 15.92M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -7.85 | |||
| Earnings Per Share Growth | -95.79% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 0.01 | |||
| Price/Book (Q) | -0.06 | |||
| Enterprise Value/Revenue (TTM) | 0.35 | |||
| Price | $0.01 | |||
| Enterprise Value/EBITDA (TTM) | -1.46 | |||
| Enterprise Value/EBIT | -1.18 | |||
| Market Cap Category | Nano Cap | |||
| Dividends and Shares | BIOLQ - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 36.08M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | BIOLQ - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 949 361 1200 | |||
| Address | 27042 Towne Centre Drive Foothill Ranch, CA 92610-2811 | |||
| Website | www.biolase.com | |||
| Country | United States | |||
| Year Founded | 1984 | |||
| Profitability | BIOLQ - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -29.36% | |||
| Profit Margin | -34.84% | |||
| Management Effectiveness | BIOLQ - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -25.61% | |||
| Return on Equity | -- | |||
| Income Statement | BIOLQ - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 46.03M | |||
| Total Revenue (TTM) | 46.03M | |||
| Revenue Per Share | $1.28 | |||
| Gross Profit (TTM) | 15.85M | |||
| EBITDA (TTM) | -10.90M | |||
| EBIT (TTM) | -13.52M | |||
| Net Income (TTM) | -16.04M | |||
| Net Income Avl. to Common (TTM) | -16.04M | |||
| Total Revenue Growth (Q YOY) | -0.65% | |||
| Earnings Growth (Q YOY) | 68.88% | |||
| EPS Diluted (TTM) | -7.85 | |||
| EPS Diluted Growth (Q YOY) | 99.64% | |||
| Balance Sheet | BIOLQ - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 3.44M | |||
| Cash Per Share (Q) | $0.10 | |||
| Total Current Assets (Q) | 19.43M | |||
| Total Preferred Equity (Q) | 1.93 | |||
| Total Equity (Q) | -3.30M | |||
| Current Ratio (Q) | 0.664 | |||
| Book Value Per Share (Q) | -$0.14 | |||
| Total Assets (Q) | 27.24M | |||
| Total Current Liabilities (Q) | 29.28M | |||
| Total Debt (Q) | 17.11M | |||
| Total Liabilities (Q) | 30.54M | |||
| Total Common Equity (Q) | -5.23M | |||
| Cash Flow | BIOLQ - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | 288.00K | |||
| Cash from Financing (TTM) | 8.59M | |||
| Net Change in Cash (TTM) | -4.37M | |||
| Levered Free Cash Flow (TTM) | -5.73M | |||
| Cash from Operations (TTM) | -13.43M | |||
